Gene editing trial starts
RecordSTO-KZ83Q2KSXP-ZY497HS547-03DW7E
United States · 2022
Gene editing trial starts in the United States were 13 in 2022 (ClinicalTrials.gov).
- Publisher
- ClinicalTrials.gov
- Authority tier
- T1 Official
- Locator
- totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States.
- Retrieved
- 27 Sep 2026
- Status
- Verified
What the source says
{"totalCount":13,"studies":[
Checked: the figure 13 is stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_KZ83Q2KSXPZY497HS54703DW7E
Other formats: MLA, Chicago, BibTeX
- MLA
- ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States." 2022, https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Accessed 27 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_KZ83Q2KSXPZY497HS54703DW7E.
- Chicago
- ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States." 2022. https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Accessed September 27, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_KZ83Q2KSXPZY497HS54703DW7E.
- BibTeX
- @misc{clinicaltrialsgo2022ctgov03dw7e, author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}}, title = {ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States}, year = {2022}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_KZ83Q2KSXPZY497HS54703DW7E}, note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR\%20OR\%20Cas9\%20OR\%20Cas12\%20OR\%20\%22base\%20editing\%22\%20OR\%20\%22base\%20editor\%22\%20OR\%20\%22prime\%20editing\%22\%20OR\%20\%22gene\%20editing\%22\%20OR\%20\%22genome\%20editing\%22\%20OR\%20\%22zinc\%20finger\%20nuclease\%22\%20OR\%20TALEN\%20OR\%20exagamglogene\%20OR\%20NTLA-2001\%20OR\%20NTLA-2002\%20OR\%20nexiguran\%20OR\%20lonvoguran\%20OR\%20VERVE-101\%20OR\%20VERVE-102\%20OR\%20BEAM-101\%20OR\%20BEAM-302\%20OR\%20EBT-101\%20OR\%20EDIT-101\%20OR\%20CTX310\%20OR\%20\%22epigenetic\%20editing\%22\%20OR\%20CTX320\%20OR\%20YOLT-101\%20OR\%20YOLT-201\%20OR\%20ART001\%20OR\%20CS-101\&filter.advanced=AREA\%5BStudyType\%5DINTERVENTIONAL\%20AND\%20AREA\%5BStartDate\%5DRANGE\%5B2022-01-01\%2C2022-12-31\%5D\%20AND\%20AREA\%5BLocationCountry\%5D\%22United\%20States\%22\&countTotal=true\&pageSize=1\&fields=NCTId. Accessed September 27, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- ClinicalTrials.gov (U.S. National Library of Medicine) · homepage ↗
- Authority tier
- Tier 1 · Multilateral Official
- Report
- ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States
- Type
- Dataset
- Published
- —
- Locator
- totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States.
- Retrieved
- 27 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- Public domain
Verification
- Status
- Verified
- Review protocol
- pipeline:ctgov-api-totalcount-verified
- Checked on
- 27 September 2026
- Last revision
- 27 September 2026
- Permanent URL
- /stat/stat_KZ83Q2KSXPZY497HS54703DW7E